Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Axisbiotix Limited currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This application is assigned to 1 distinct examiner and 1 distinct art unit. The company's active patent prosecution is currently limited to this matter.
The busiest examiner, DEVI, SARVAMANGALA, is responsible for 1 pending office action. This matches the total of 1 pending office action for the portfolio, meaning this examiner handles the active workload. With only 1 distinct art unit involved, the prosecution process is concentrated within a specific biotechnology division of the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEVI, SARVAMANGALA | 1 | 65.5% | +55.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546321 | Composition and Use Thereof | DEVI, SARVAMANGALA | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18546321 | Composition and Use Thereof | DEVI, SARVAMANGALA | 1645 | §112 | Final Rejection | — | Pending | Aug 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAxisbiotix Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sarvamangala Devi has the most, with 1 of Axisbiotix Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
